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Abstract
Pancreatic neuroendocrine tumours (pNETs) are rare and surgical resection offers the only possibility of cure for
localised disease. The role of surgery in the setting of locally advanced and metastatic disease is more
controversial. Emerging data suggests that synchronous surgical resection of pancreas and liver may be associated
with increased survival. We report two cases of synchronous, one stage multivisceral resections for pNET and
associated reconstruction. We highlight the technical issues involved in such extensive resections and demonstrate
that one stage multivisceral operations can be achieved safely.
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Background
Pancreatic neuroendocrine tumours (pNETs) are rela-
tively rare with an annual incidence of two to three
cases per million of population [1]. Such tumours can
be classified as functional or non-functional. In earlier
studies, functional tumours were more common than
non-functional tumours. However, more recent data
suggests that up to 85% of pNETs are non-functioning
[1,2]. Patients with functional tumours usually present
earlier due to unique clinical symptoms caused by hor-
mone hypersecretion. In contrast, non-functioning
tumours present later with non-specific symptoms and
patients often have metastatic disease at the time of
diagnosis [3].
TNM staging, the modified WHO classification and
Ki-67 proliferative index may predict recurrence, but are
less useful in individual cases due to the unpredictable
nature of this disease [4]. For a solitary pNET, resection
remains the best option for long term cure [3]. Retro-
spective studies also suggest that synchronous resection
of the primary and metastatic liver disease is also asso-
ciated with improved survival outcomes [3,5,6].
Surgical options in the presence of locally advanced
disease are more controversial however. Current clinical
guidelines recommend aggressive surgical treatment [7].
However, these patients typically require complex, tech-
nically demanding resections that push the boundaries
of not only technical feasibility, but also acceptable mor-
bidity and mortality.
Whilst there is mounting evidence justifying such a
radical approach [3,5,6,8], prospective, multi-centre stu-
dies reporting disease free and functional quality of life
survival outcomes do not presently exist for this sub-
group of pNET patients, thus making clinical decision
making problematic. We highlight two further examples
of large pancreatic neuroendocrine tumours requiring
multivisceral resection to demonstrate that complex one
stage operations can be achieved safely.
Case Report 1
A 63 year old woman presented with a six month his-
tory of progressive upper abdominal discomfort and
intermittent vomiting. History was significant only for
left breast cancer for which she had undergone a mas-
tectomy seven years earlier.
Clinically she possessed a firm right upper quadrant,
tender mass. Blood tests showed mildly deranged liver
function tests (ALP: 279IU/l; GGT: 282IU/l) and an ele-
vated serum chromogranin A level (CgA; 52IU/l; range:
0-17.2). Computed tomography (CT) of the abdomen
showed a well demarcated head of pancreas lesion (4 ×
4 cm) and a large heterogeneous right hemi-liver lesion
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(15 × 15 × 12 cm). Both lesions showed uptake on a
subsequent octreotide scan. An endoscopic ultrasound
was also performed and fine needle biopsies of both
pancreas and liver lesions were shown to be consistent
with a diagnosis of neuroendocrine tumour. Laparo-
scopy was negative for further dissemination of disease
and the multi-disciplinary oncology team meeting con-
sensus was in favour of surgical resection.
A midline laparotomy was performed and an extended
right hepatectomy commenced. Following mobilisation
of the right colon, the duodenum was Kocherised. The
avascular plane anterior to the inferior vena cava (IVC)
was dissected and a nylon tape passed behind the liver.
This facilitated ultrasonic dissector division of hepatic
parenchyma with the “hanging manoeuvre”. Inflow
occlusion was not necessary. At this point, the right and
middle hepatic veins were divided. The right portal vein
was transected and oversewn transversely to avoid main
portal vein trunk stenosis. This completed an extended
right hepatectomy (segments 1, 4a, 5, 6, 7 and 8) and
the specimen was removed (Figure 1).
This was followed by a pancreatoduodenectomy. The
lesser sac was entered, the infra-colic compartment
examined and tumour mobility (within context of portal
vein and superior mesenteric vasculature) assessed. Fol-
lowing confirmation of resectability, the stomach
antrum and common hepatic duct were divided sequen-
tially. The neck of pancreas was then transected. The
proximal jejunum was divided and the ligament of
Treitz dissected to mobilise and remove the specimen
from the abdomen. Figure 2 shows the resection bed
following removal of liver and pancreas tumours. Recon-
struction involved a double layered, end-side pancrea-
tico-jejunostomy, an end-side hepatico-jejunostomy and
a side-side gastro-jejunostomy.
The abdomen was drained and closed. Total operative
time was 6.5 hours with an estimated blood loss of 750
ml. The post-operative period was complicated by an
intra-abdominal collection which was managed with
percutaneous drainage.
Histopathological examination showed a well differen-
tiated pancreatic neuroendocrine carcinoma 45 mm in
diameter, with a mitotic rate of nine mitoses per 10
high power fields (hpf) and a Ki-67 proliferative index of
15%. All microscopic margins were clear. A completely
excised single liver metastasis, 158 mm in diameter, was
identified in the hepatectomy specimen with associated
cytological atypia and focal coagulative necrosis. None
of 33 resected lymph nodes were involved.
The patient remains well two years following resec-
tion. Serial CT scans (at 3, 6, 12 and 24 months)
showed no evidence of recurrence and CgA levels are
normal.
Case Report 2
A 60 year old woman presented with a twelve month
history of fatigue, anorexia, weight loss and abdominal
distension. She had a history of well controlled hyper-
tension and type II diabetes mellitus.
Figure 1 Macroscopic view of extended right hepatectomy
specimen (Case 1).
Figure 2 Operative resection bed following removal of right
liver and head of pancreas tumours (Case 1).
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Liver function tests were slightly abnormal (ALP:
383IU/l; GGT: 216IU/l). CT of the abdomen demon-
strated a large pancreatic mass (13 × 9 × 5 cm) com-
pressing the confluence of the portal and superior
mesenteric veins (Figure 3a). The right colon and
antrum of the stomach also appeared to be intimately
involved with the tumour. Additionally, a 12 cm dia-
meter mixed cystic/solid mass was noted to occupy the
majority of the right hemi-liver (Figure 3b). Her serum
CgA level was elevated at 507IU/l (range: 0-17.2) and an
octreotide scan showed avid uptake within the pancrea-
tic mass and within the periphery of the liver lesion.
Laparoscopy was performed to exclude additional
peritoneal disease and biopsies of the right liver tumour
were taken. Biopsy specimens confirmed the diagnosis
of a neuroendocrine tumour with a Ki-67 index of 4%.
At a multidisciplinary oncology team meeting, consen-
sus of opinion was that the patient should be offered
resection. Volumetric analysis demonstrated a 24%
future remnant liver volume. A right portal vein emboli-
sation was performed with a view to inducing left lobe
hypertrophy. Four weeks later, reassessment of the liver
volume confirmed that the future left lateral section
remnant volume had increased to 32%.
A midline laparotomy was performed. Exploration
confirmed that the pancreatic mass had invaded into the
greater curvature of the stomach and adjacent transverse
colon. Initially, an extended right hepatectomy (seg-
ments 4a, 5, 6, 7 and 8) was performed including exci-
sion of the terminal part of the middle hepatic vein
flush with the IVC. The left hepatic duct was divided,
and the right hepatic artery was divided 1 cm distal to
its confluence with the left hepatic artery. An extended
Kocher’s manoeuvre was performed and the posterior
relations of the mass were assessed. It was evident that
while the IVC and aorta were free from disease, the por-
tal vein (PV) and coeliac axis were involved by tumour
and would require resection, en-bloc with the mass. The
superior mesenteric vein (SMV) and artery (SMA) were
identified in the infra-colic compartment and the dissec-
tion plane was maintained along the SMA to its aortic
origin. The right colon and small bowel were mobilised
using the Cattell-Braasch manoeuvre [9].
The involved PV and SMV were then transected
above and below the mass, respectively. Continuity was
restored by direct end to end anastomosis; facilitated by
the extra mobility gained from the preceding hepatic
resection and small bowel mesenteric mobilisation. Fol-
lowing this, an interposition saphenous vein graft was
placed from the aorta to the junction of the right and
left hepatic artery. The common hepatic artery was
divided and the coeliac axis was divided and ligated
flush with the aorta. The dissection plane was now con-
tinued to the left of the aorta along Gerota’s fascia. The
left adrenal gland was adherent to the tumour and was
included in the en-bloc specimen. The terminal ileum,
descending colon and gastro-oesophageal junction were
all divided, thus completing the resection which con-
sisted of the stomach, spleen, pancreas, duodenum, left
adrenal, right colon and transverse colon (Figure 4a, b).
Reconstruction consisted of a oesophago-jejunostomy
and hepatico-jejunostomy (Figure 5). Finally an end
Figure 3 a: CT demonstrating pancreatic mass with superior mesenteric/portal vein encasement and associated liver metastasis (Case
2); b: CT demonstrating right liver metastasis (post embolization; Case 2).
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ileostomy and colonic mucous fistula were fashioned on
the left abdominal wall. The total operative time was 16
hours and the intraoperative blood loss was 1850 mls.
Histopathological examination revealed a well differ-
entiated pancreatic neuroendocrine carcinoma 95 mm
in diameter with a mitotic rate of one mitosis per 10
hpf and a Ki-67 proliferative index of 2% (Figure 6). The
tumour demonstrated local invasion into the retroperi-
toneum, colon, stomach and left adrenal gland, but all
microscopic margins were clear. A completely excised
single liver metastasis, 90 mm in diameter, was found in
the hepatectomy specimen, and two out of 24 lymph
nodes were involved by metastatic carcinoma.
The post-operative course was complicated by refrac-
tory chylous ascites, which was successfully managed
with a peritoneo-venous shunt on the twenty fourth
post-operative day. She was discharged from hospital
without any further complications.
Follow up showed a good functional recovery from
surgery with independent resumption of activities of
daily living by one month. CT at three and six months
showed post-operative changes only. Nine months
after surgery, the patient began to complain of left
subscapular chest wall pain. A gallium 68 scan con-
firmed recurrence of tumour in the ribs bilaterally,
mediastinum and in the remnant left liver. Slow release
octreotide therapy was commenced and transarterial
chemoembolisation (TACE) therapy was pursued for
local control of hepatic disease. Bony disease was trea-
ted with radiotherapy.
Disease appeared static until 12 months. Systemic che-
motherapy was commenced upon medical oncology
advice with everolimus. Unfortunately, she developed
severe haematological and renal complications as a con-
sequence and died 15 months after her initial operation.
Discussion
Successful multivisceral resections of this magnitude
have not been previously described. The low incidence,
variable biological behaviour of pNETs and a reluctance
to undertake multi-visceral resections for advanced dis-
ease have been significant impediments to publishing
large volume, prospective therapeutic studies.
Despite this, the current European Neuroendocrine
Tumour Society (ENETS) guidelines support “aggressive
surgery” where tumours larger than 2 cm and/or locally
advanced disease may necessitate en-bloc resection of
adjacent organs [7]. Whilst such guidelines are based
upon relatively small retrospective studies [5,6], they
demonstrate that a successful outcome is possible fol-
lowing resection of limited locally advanced disease with
acceptable morbidity and mortality. Hellman et al.
(2003) conclude that “conventional contraindications to
surgical resection, such as superior mesenteric vein inva-
sion and nodal or distant metastases, should be recon-
sidered in patients with advanced neuroendocrine
tumors”.
Given potential morbidity, mortality and the lasting
impact that such operations may have upon patients, a
survival advantage needs to be demonstrated to justify
aggressive management. Retrospective analyses have
shown some survival benefit following surgery for locally
advanced disease [6,10,11]. However, as articulated in
the ENETS guidelines, this evidence suffers from a het-
erogeneous patient/tumour cohort (various stages of dis-
ease; mixed functioning/non-functioning tumours) and
multi-modality treatment strategies that make conclu-
sions regarding aggressive surgery specifically, difficult
to deduce.
With regard to liver metastases, a number of studies
have shown that combined resection of the primary
Figure 4 a: Macroscopic view of en bloc primary tumour resection specimen (Case 2); b: pancreatic tumour invasion of lesser sac and
posterior stomach wall (Case 2).
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lesion and small volume metastatic liver disease
improves survival outcomes [6,8,12]. ENETS guidelines
site the possibility of recurrent liver disease and suggest
that resection should only be pursued if at least 90% of
the tumour volume can be removed [7]. Resecting the
primary while leaving hepatic metastases in situ does
not confer a survival advantage and should not be
undertaken [13].
Figure 5 Illustration depicting vascular and enteric reconstruction post resection (Case 2).
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Management of inoperable metastatic liver disease
may involve a spectrum of multi-modality therapy. In
highly selected cases even liver transplantation may be
considered [14], but most patients generally possess dis-
ease only amenable to loco-regional ablative therapies
(such as TACE) or systemic treatment. The use of
somatostatin analogues have traditionally been employed
and significantly slow disease progression in non-func-
tioning disseminated pNETs [15]. More recently, the
tyrosine kinase inhibitor sunitinib has demonstrated
Phase 3 trial efficacy in management of disseminated
pNET, leading to prolonged progression and treatment
free survival [16].
Both cases demonstrate that a complex multivisceral
resection with synchronous hepatectomy can be per-
formed safely, provided that the surgeon executes the
multistep procedure in an appropriate sequence, in
order to avoid the many potential pitfalls. For example,
a staged approach with initial extended hepatectomy
may have made a subsequent laparotomy and dissection
in the supracolic compartment more hazardous. More
importantly, in Case 2, initial resection of the primary
lesion may have rendered subsequent attempts at indu-
cing future remnant liver hypertrophy ineffective, due to
the absence of the trophic effect of endogenous insulin.
Early liver resection also aided further dissection as it
provided increased manoeuvrability and facilitated selec-
tive control of the portal vein without further need for a
Pringle manoeuvre. Additionally, sequential resection/
reconstruction of the portal vein and coeliac axis mini-
mised hepatic ischaemia. Had prolonged portal vein and
coeliac axis clamping been required, the obliterated
umbilical vein could have been used as a potential
bypass conduit.
Chylous ascites was a predictable complication in Case
2, given such extensive retroperitoneal dissection. In this
Figure 6 a: at low magnification the pancreatic tumour displayed a typical trabecular architecture; b: at higher power the typical
neuroendocrine nuclear features characterised by dispersed chromatin are observed; c: Immunohistochemistry for Chromogranin was
diffusely strongly positive; d: Immunohistochemistry for Ki-67 demonstrated a proliferative index of 2% (original magnifications a:
100×, b, c, d: 400×; Case 2).
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situation we favoured a peritoneo-venous shunt over
repeated peritoneal taps to lower the risk of infection.
The natural history of pNETs continues to be difficult
to predict despite advances in staging, grading and clas-
sification systems. A lack of consensus within methods
of pathology reporting has also been highlighted recently
[17] and serves only to make prognostication even more
complex. To enhance clinical decision making utility,
these systems have recently been rationalised by ENETS
in the form of clinical guidelines for investigation and
management [7].
Whilst further histopathological and prognostic cri-
teria such as the Ki-67 proliferative index and mitotic
count are included, such markers may still underesti-
mate the unpredictable nature of this disease [4]. Con-
trasting proliferative markers of the two presented cases
demonstrates this point. Both cases possessed well dif-
ferentiated primary tumours. Case 1 however, showed a
much higher mitotic rate (9 vs 1 mitoses per10 hpf) and
Ki-67 index (15 vs 2%). Thus, despite histological evi-
dence of relatively indolent tumour biology, Case 2 ulti-
mately possessed a more aggressive tumour clinically,
leading to early recurrence despite a margin negative
resection. Although proliferative markers have been vali-
dated and correlate with prognosis [18], our current
understanding of pNET tumour biology at a molecular
level demands further attention to explain tumour het-
erogeneity. This will be necessary before translational
benefits (such as validated biomarkers to assist diagno-
sis, treatment and prognostication) can be derived.
Clinical decision making therefore remains difficult in
individual cases and deciding which patients should be
offered resection continues to challenge experienced clin-
icians [7]. Beyond tumour biology and technically achiev-
able surgical resection, the clinician must also bear in
mind patient co-morbidity, post-operative quality of life
and preference when considering management options.
Conclusion
Complex multivisceral resections of neuroendocrine
tumours can be achieved safely with appropriate preo-
perative planning and surgical expertise. We advocate
resection of primary and secondary liver disease in a
one stage procedure where patient co-morbidity and
technical expertise allow. Further studies are required to
justify and standardise the approach to aggressive sur-
gery for locally advanced disease.
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